NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in…
BELTSVILLE, Md., Oct. 04, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class…